CagriSema (Subcutaneous)
Obesity, Type 2 Diabetes
Phase 3Active
Key Facts
About Novo Nordisk
Novo Nordisk's mission is to defeat diabetes and other serious chronic diseases through innovative biopharmaceutical solutions. The company has achieved transformative success with its GLP-1-based therapies, Ozempic® and Wegovy®, catalyzing a new era in metabolic care and generating massive commercial growth. Its strategy is built on expanding the clinical utility of its core platforms, advancing a deep pipeline of next-generation multi-agonists and novel modalities, and scaling manufacturing to meet global demand. Recent milestones include the US approval of the first once-weekly basal insulin, Awiqli®, and promising Phase 2 data for a triple agonist.
View full company profileTherapeutic Areas
Other Obesity, Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| ThermoStem | BioRestorative Therapies | Preclinical |
| Danuglipron (GLP-1/GIP) | Pfizer | Phase 3 |
| PF-07081532 (GLP-1R) | Pfizer | Phase 3 |
| Oral CagriSema | Novo Nordisk | Phase 2 |